Wave Life Sciences stock has had a tough start to 2026, with a sharp year to date decline set against valuation checks that point to a stock that still looks expensive on traditional measures.

• Year to date, Wave Life Sciences is down 60.9%, which means recent gains over the past week and month have not yet repaired the earlier damage.
• Recent progress on its US redomiciliation and RNA programs for obesity and alpha-1 antitrypsin deficiency can support higher growth expectations, but execution and clinical risk remain central to how investors will price the stock.
• Wave Life Sciences currently passes 0 of 6 valuation checks, which suggests it does not screen as a clear bargain on Simply Wall St’s broader framework, even after the sell off, according to this valuation summary.

The issue now is whether the current share price already reflects the risks around Wave Life Sciences or if investors are still paying too much for the potential upside.

Has Wave Life Sciences Run Too Far on Sales?

P/S is often a cleaner way to compare early stage biotech stocks like Wave Life Sciences, because earnings and cash flows are still heavily loss making while revenue provides at least some common yardstick.

Wave Life Sciences trades on a P/S ratio of 16.7x, which is far above the Pharmaceuticals industry average of 6.7x and the peer average of 1.9x. The Fair Ratio implied by Simply Wall St’s framework is 1.3x. This means the current multiple sits many turns above what the model suggests would be reasonable given the company’s risk profile and fundamentals. Because this gap is very wide, the figure is better read as a signal that the stock screens as very expensive on sales rather than as a precise target level.

Despite progress on the US redomiciliation and RNA programs that has supported sentiment around Wave Life Sciences, the stock still trades at a sizeable premium to typical sector P/S levels.

On this P/S measure, Wave Life Sciences appears overvalued relative to both peers and the modelled fair multiple.

The Wave Life Sciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Wave Life Sciences' stock sit alongside the valuation work above, spelling out in plain terms what future growth, margins and earnings would need to look like for the company to be worth materially more or less than today. They live on Simply Wall St's Community page. Where a single ratio or model gives one number, these frameworks unpack the future that number rests on so you can watch how the real story lines up over time.

One of the top community narratives on Wave Life Sciences: 84% undervalued

"Wave's PRISM platform advances in stereopure oligonucleotides position the company to play a significant role in the next generation of RNA therapeutics, with potential applications in both rare and common diseases."

Do you think there's more to the story for Wave Life Sciences? Head over to our Community to see what others are saying!

The Bottom Line

For Wave Life Sciences, the market multiple view points to an overvalued stock, with the current P/S ratio sitting well above both industry peers and the modelled fair ratio. That wide gap reflects investors placing a high price on the potential of the company’s RNA programs despite ongoing execution and clinical risk. From here, the key question is whether future progress on those programs ultimately earns that premium or whether the valuation needs to move closer to more typical sector levels.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.